Simone M. Peek


  • Tuesday, October 4, 2011
    Medical device companies that do business in emerging markets face the prospect of great reward as well as great risk. Increasingly, one of the major risks is exposure to the U.S. Foreign Corrupt Practices Act ("FCPA") and similar international anti-bribery laws and regulations. A key to mitigating this risk is to have a strong anti-corruption...